Horizon provides assay development and drug screening services powered by our precision gene-editing and human isogenic cell-line platforms.
Clients are able to access our patient-relevant X-MAN™ genetically defined cell lines to study how specific cancer genes and mutations affect sensitivity to therapeutic compounds. We also offer research services using standard non-isogenic cancer cell lines to supplement our isogenic cell line offering, and have a bank of over 120 lines ready to use.
Our range of optimized cellular assays has applications at many points during the drug discovery process including:
|Viability (multiple assay readouts)||Apoptosis assays
||3D assays (spheroids, methylcellulose)||siRNA/shRNA knockdown|
|Colony formation (2D)||Immunofluorescence
||RNA / cell pellet / lysate preparation|
|Soft agar (3D)
||DNA damage assays
||Expression profiling (qRTPCR, protein)|
|Combination drug assays||Cellular ELISA
||Tubulin polymerisation assay|
|Cell panel profiling (standard and X-MAN™ isogenic cell lines)||FACS
|Invasion and migration assays||Autophagy assay
||Reactive oxygen species assays|
Of particular value are several assays designed to recreate the tumor microenvironment, enabling analysis of parameters such as hypoxia, 3-dimensional growth, senescence, autophagy and drug resistant pathway responses. These assays, particularly when deploying isogenic X-MAN™ cell lines, clearly demonstrate the role that endogenous mutations play in driving disease and reinforce the importance of placing these cells under tumor relevant conditions in order to illicit the true disease phenotypes and drug responses seen in the clinic.
In combination with CrownBio Incorporated we can provide an integrated solution that can include both in vitro and in vivo studies.
Horizon is also able to develop customized assays specifically designed to address key scientific questions. For example, assays utilizing activity-dead cell lines to determine whether known effect is based on structural or functional causes.